forkhead box D4 like 1Genealiases: FOXD5 · bA395L14.1
Q-omics provides the consensus-scored FOXD4L1 profile across patient tissues and cancer cell-line models. FOXD4L1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FOXD4L1 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, FOXD4L1 RNA expression shows 14,769 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRP, and UVM as cancer lineages where FOXD4L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXD4L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXD4L1 survival associations across molecular data types. FOXD4L1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXD4L1 RNA expression–survival associations across cancer types. High FOXD4L1 expression shows unfavorable associations in ACC, KIRC, READ and MESO, but favorable associations in HNSC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FOXD4L1 RNA expression.
This table summarizes FOXD4L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for FOXD4L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXD4L1 shows higher tumor expression in KIRP, HNSC, LIHC, UCEC, STAD and BRCA. The KIRP box plot shows higher FOXD4L1 RNA expression in tumor versus normal tissue (log2 FC = +0.299, t-test p = .001).
This table shows molecular features associated with FOXD4L1 in patient tissues and cancer cell lines. In patient samples, FOXD4L1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXD4L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
